drugset
drugset / Trial / NCT05389462

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

NCT05389462 ↗

Phase 1 Terminated 128 enrolled ADC Therapeutics S.A.
Non-randomizedSequentialOpen-labelTreatment

Summary

The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601 monotherapy and in combination with gemcitabine.

Timeline

Start
2022-07-13
Primary completion
2025-04-17
Completion
2025-04-17

Outcome

Outcome not reported

Stopped: “Sponsor decided to halt further development of ADCT-601”

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule — Intravenous
Subject MIPASETAMAB UZOPTIRINE Unknown — Intravenous

Indications

cancer